Abstract: The use of polyunsaturated fatty acids of the &ohgr;-3 series such as eicosapentaenoic acid (EPA, C20:5 &ohgr;-3), docosahexaenoic acid (DHA, C22:6 &ohgr;-3), or their pharmaceutically acceptable derivatives is described for the primary prevention of major cardiovascular events in subjects who have not undergone previous infarct episodes.
Abstract: New injectable pharmaceutical formulations are described, containing a partricin derivative in the form of a free base as the active ingredient, or a pharmaceutically acceptable water-soluble salt thereof in a solubilizing/dispersing medium made up of a lipid and/or phospholipid emulsion in water, a procedure to obtain them, and the use of the formulations in the treatment of phathologies sensitive to the action of partricin derivatives.
Type:
Grant
Filed:
December 22, 2000
Date of Patent:
July 1, 2003
Assignee:
Quatex N.V.
Inventors:
Tiberio Bruzzese, Valerio Maria Ferrari
Abstract: The use of polyunsaturated fatty acids of the &ohgr;-3 series such as eicosapentaenoic acid (EPA, C20:5 &ohgr;-3), docosahexaenoic acid (DHA, C22:6 &ohgr;-3), or their pharmaceutically acceptable derivatives is described for the primary prevention of major cardiovascular events in subjects who have not undergone previous infarct episodes.
Abstract: A complex containing N'-dimethylaminoacetylpartricin A dimethylaminoethylamide, as a salt or as the free base, and cholesterol 3-sulphate, in a molar ratio between 1:0.5 and 1:10, respectively.